[1] Lin TY, Shekar AO, Li N, et al. Incidence of abnormal liver biochemical tests in hyperthvroidism. Clin Endocrinol,2017, 86(5):755-759. [2] 贾晨雨,郭丹,林震宇,等.甲状腺功能亢进性肝损害与甲巯咪唑继发性肝损害的临床比较研究.临床内科杂志,2020,37(1):23-26. [3] 明慧,张桂芝,李玮,等.分化型甲状腺癌患者肝功能损害与甲状腺功能减退的关系.天津医科大学学,2015,90(6):514-517. [4] Waring AC, Rodondi N, Harrison S, et al. Thyroid function and prevalent and incident metabolic syndrome in older adults: the Health, Ageing and Body Composition Study. Clin Endocrinol (Oxf),2012,76(6):911-918. [5] 程艳冬,杨东辉,许碧云,等.2 型糖尿病患者肝功能损害特征以及原因分析.医学研究杂志,2017,46(10):76-80,e83. [6] Björkström K, Franzén S, Eliasson B, et al. Risk factors for severe liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol,2019,17(13):2769-2775,e4. [7] Simon TG, King LY, Chong DQ, et al. Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: results from two prospective cohort studies. Hepatology,2018,67(5):1797-1806. [8] Paschou SA, Polyzos SA, Anagnostis P, et al. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Endocrine,2020, 67(1):1-8. |